Albumin News and Research

RSS

Launch date announced for Abraxane to treat metastatic breast cancer

American Pharmaceutical Partners announced today that February 8, 2005 is the launch date of Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Abraxane will be marketed by the national sales force of Abraxis Oncology, APP's proprietary sales and marketing division.

25 Jan 2005

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer.

9 Jan 2005

FDA approves Abraxane for metastatic breast cancer

American Pharmaceutical Partners, Inc. and American Bioscience, Inc. (ABI) announced that the U.S. Food and Drug Administration (FDA) has approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer.

9 Jan 2005

Transplanted bone marrow cells reduce liver fibrosis in mice

Transplanted bone marrow cells can reduce carbon tetrachloride-induced liver fibrosis in mice and significantly improve their survival rates, according to a new study

8 Dec 2004

Israeli developed fruit called pomelit, lowers blood cholesterol

People who eat the Israeli-developed fruit known in Hebrew as pomelit (a cross between a grapefruit and a pomelo) or drink its juice regularly will be able to lower their blood cholesterol and increase their blood antioxidant activity, thus improving their chances of preventing blocked heart arteries and heart attacks, says a researcher at the Hebrew University of Jerusalem.

30 Nov 2004

Sit down rounds improve outcomes for kidney dialysis patients

"Sit-down" medical rounds, during which a health care team meets to review a patient's medical record and discuss short- and long-term needs, are associated with better outcomes for kidney dialysis patients, a Johns Hopkins-directed study has found.

17 Nov 2004

Human Genome Sciences announces agreement with GSK for development of drug to treat diabetes

Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.

26 Oct 2004

Wyeth gets approval for needle-less syringe for the treatment of hemophilia

Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.

14 Sep 2004

Correlation between HCV viral load and severity of liver disease

The significance of hepatitis C virus (HCV) serum titers (HCV viral load) has been examined in several clinical situations. There is much evidence that patients with a lower viral load have better response rates to anti-viral therapy compared to those with higher levels.

9 Aug 2004

Isolated soy protein shown to benefit type 2 diabetics

Isolated soy protein added to the diets of 14 men, all military veterans under treatment for advanced stages of type 2 diabetes, significantly lowered unwanted proteins in their urine and slightly raised desired HDL cholesterol levels in their blood, researchers say.

2 Aug 2004

Major campaign victory will create safer environments for children with food allergies

About 11 million people - roughly 1-in-25 Americans - are now believed to be affected by one or more food allergies, a disease triggered by the ingestion or contact with certain foods that may cause life-threatening reactions, or anaphylaxis, according to a recent Food Allergy & Anaphylaxis Network nationwide survey.

21 Jul 2004

World's largest study into intensive care

The University of Sydney has played a part in the world's largest study into intensive care, which contains significant findings for doctors all over the world.

16 Jun 2004

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Investigational drug Abraxane™ (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).

15 Jun 2004

Bone marrow stem cells exposed to damaged liver tissue quickly convert into healthy liver cells

Bone marrow stem cells, when exposed to damaged liver tissue, can quickly convert into healthy liver cells and help repair the damaged organ, according to new research from the Johns Hopkins Kimmel Cancer Center.

2 Jun 2004

Human Genome Sciences has begun dosing patients with chronic hep C drug

Human Genome Sciences, Inc. announced today that it has begun dosing patients in a Phase 2 clinical trial of Albuferon™ (albumin-interferon alpha) in patients with chronic hepatitis C who are naïve to interferon-alpha treatments.

27 May 2004

Causes of hepatitis and potential therapies that may improve care presented in study

Hepatitis, a potentially serious disease caused by a virus that attacks the liver, is a major problem worldwide. Hepatitis A is generally food-borne, while hepatitis B and C spread primarily through parenteral or sexual routes. Hepatitis B and C can be life-long, potentially deadly chronic infections.

19 May 2004

Sainsbury's potato chips cause allergic reactions

The Food Standards Agency is today warning people with allergies who have bought Sainsbury's potato wedges that some could cause an allergic reaction.

30 Apr 2004

New device filters blood supplies on-site reducing the possible transmission of Creutzfeldt-Jakob disease

ProMetic Life Sciences Inc. has announced today that its joint venture with the American Red Cross, Pathogen Removal and Diagnostic Technology Inc. ("PRDT"), has confirmed that treatment of TSE spiked red blood cell concentrate with its Prion Reduction Device results in a significant decrease in associated infectivity.

5 Apr 2004